A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects



Status:Terminated
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:5 - Any
Updated:6/16/2018
Start Date:May 1, 2013
End Date:October 1, 2016

Use our guide to learn which trials are right for you!

An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Drisapersen in US and Canadian Subjects With Duchenne Muscular Dystrophy.

This is a phase III, multicenter, open-label, uncontrolled extension study in male subjects
with DMD open to eligible US and Canadian subjects who previously participated in the
following studies of drisapersen: DMD114876, DMD114044 and DMD114349. Subjects will receive
6mg/kg subcutaneous drisapersen on a weekly basis. For subjects who have previously
experienced significant safety or tolerability issues or who experience these during the
study, there is the potential of an alternate intermittent dosing arm that will be given as a
regimen of 6 mg/kg weekly for 8 weeks followed by 4 weeks off treatment. For subjects who
experience or have previously experienced significant safety/tolerability issues, side
effects or reactions or intermittent dosing, intravenous dosing will be made available.

In Part A of the study (DMD115501, original protocol), 21 subjects entered the study at 3 US
sites and completed up to 14 weeks of treatment, and up to 22 weeks of follow-up. This
protocol amendment, Part B of the study will include up to 13 more US and Canadian centers,
and up to 51 more subjects. In total the study will enroll approximately 72 subjects. All
subjects will commence Part B at screening and follow the study schedule.

The primary dosing arm is drisapersen 6 mg/kg as SC injection(s) once a week. For subjects
who have previously experienced significant safety or tolerability issues or who experience
these during the study, there is the potential of an alternate intermittent dosing arm that
will be given as a regimen of 6 mg/kg/wk for 8 weeks followed by 4 weeks of treatment. For
subjects who experience or have previously experienced significant safety/tolerability
issues, intravenous dosing will be made available.

This study does not have a minimum duration of participation. Subjects will have varying
times of study participation depending on when they enter from one of the eligible studies,
and will be permitted to continue in this study until such a time that they withdraw based on
protocol-defined criteria, or BioMarin stops the study.

Inclusion Criteria:

- Participation in an eligible drisapersen study as follows:

(A) Prior DMD114876 subjects: Subjects who completed both the 24 week double-blind
treatment and 24 week post-treatment phases in study DMD114876 OR Subjects who withdrew
from the treatment portion of study DMD114876 due to meeting laboratory safety stopping
criteria may be eligible to enrol in the extension study if: the laboratory parameters that
led to stopping have resolved; the principal investigator (PI) considers the benefit of
further treatment with drisapersen outweighs the risk to the individual subject; and
following consultation with the Medical Monitor (B) Prior DMD114044 Subjects: US subjects
who completed study DMD114044 in another country and who want to return to the US to
participate in study DMD115501, upon agreement by a DMD115501 Investigator OR US citizens
who participated in DMD114044 but who had to withdraw from the study due to meeting
laboratory safety stopping criteria may be eligible to enrol in DMD115501 if: the
laboratory parameters that led to stopping have resolved; the PI considers the benefit of
further treatment with drisapersen outweighs the risk to the individual subject; and
following consultation with the Medical Monitor and upon agreement by a DMD115501
investigator (C) Prior DMD114349 Subjects: US subjects who participated in and completed
study DMD114044 in another country and who entered into the ongoing open-label extension
study DMD114349 in a country outside the US who wish to withdraw from DMD114349 and return
to the US to participate in study DMD115501, upon agreement by a DMD115501 investigator.

Canadian subjects who participated in the DMD114349 study OR Canadian subjects who withdrew
from the treatment portion of the study DMD114349 due to meeting laboratory safety stopping
criteria may be eligible to enroll in the extension study if the laboratory parameters that
led to stopping have resolved; the PI considers the benefit of further treatment with
drisapersen outweighs the risk to the individual subject; and following consultation with
the Medical Monitor.

- Continued use of glucocorticoids for a minimum of 60 days prior to study entry with a
reasonable expectation that the subject will remain on steroids for the duration of
the study. Changes to or cessation of glucocorticoids will be at the discretion of the
PI in consultation with the subject/parent and the Medical Monitor. If subject is not
on steroids, involvement in the study needs to be discussed with the medical monitor.

- Willing and able to comply with all protocol requirements and procedures (with the
exception of those assessments requiring a subject to be ambulant, for those subjects
who have lost ambulation)

- Able to give informed assent and/or consent in writing signed by the subject and/or
parent(s)/legal guardian (according to local regulations)

Exclusion Criteria:

- Subject had a serious adverse experience or who met safety stopping criteria that
remains unresolved from studies DMD114876, DMD114044, or DMD114349, which in the
opinion of the investigator could have been attributable to study medication, and
which is ongoing. Once resolved, subject may be eligible to enrol following PI
consultation with the Medical Monitor

- Use of anticoagulants, antithrombotics or antiplatelet agents, or previous treatment
with investigational drugs except for drisapersen, within 28 days of the first
administration of study medication

- Participation in any other investigational clinical trial within 30 days prior to the
start of screening, or during this clinical study. If subject has participated in any
other study within 6 months, this should be discussed with the medical monitor prior
to study entry.

- History of significant medical disorder which may confound the interpretation of
either efficacy or safety data (e.g. current or history of renal or liver
disease/impairment, history of inflammatory illness)

- Symptomatic cardiomyopathy. If subject has a left ventricular ejection fraction <45%
at Screening, the investigator should discuss inclusion of subject in the study with
the medical monitor

- A platelet count under the lower limit of normal at screening. A re-test within the
screening period is permissible and if within normal range the subject may enter the
study.
We found this trial at
11
sites
700 Childrens Drive
Columbus, Ohio 43205
(616) 722-2000
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
?
mi
from
Columbus, OH
Click here to add this to my saved trials
707 North Broadway
Baltimore, Maryland 21205
443-923-9200
Kennedy Krieger Institute While not officially part of Johns Hopkins Medicine, Kennedy Krieger Institute is...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
101 Jessup Hall
Iowa City, Iowa 52242
(319) 335-3500
University of Iowa With just over 30,000 students, the University of Iowa is one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
(612) 625-5000
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Sacramento, California 95814
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Edward C Smith, MD
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
Portland, Oregon 97239
?
mi
from
Portland, OR
Click here to add this to my saved trials
Tampa, Florida 12502
Principal Investigator: Ray Fernandez, MD
Phone: 813-972-2250
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Vancouver, British Columbia V6H 4J4
?
mi
from
Vancouver,
Click here to add this to my saved trials